BIA Separations signs agreement to commercialise novel elution technology
Agreement gives BIA Separations access to proprietary technology to better preserve integrity, infectivity and potency of immunoaffinity-purified viral vectors for gene therapy.
BIA Separations has signed a licensing agreement with the University of Zagreb to commercialize a novel elution method that helps preserve the integrity, infectivity and potency of viruses during immunoaffinity purification.
The University of Zagreb will provide BIA Separations with access to proprietary technology, while BIA Separations will market the technology to biopharma, biotech and life science industries globally. As part of the agreement, research teams from both organisations will collaborate to develop follow-on technologies to support the purification of viruses and viral vectors for research and clinical use.
One of the key disadvantages of the immunoaffinity chromatography is partial degradation of viral particles as a result of low pH conditions required for the elution. The technology overcomes this by using a concentrated solution of specifically selected amino acids and their salts, maintaining a neutral pH (6.0 – 8.0), which results in the highly effective elution from immunoaffinity chromatographic support of intact and functional viruses for gene therapy application.
BIA Separations will commercialize the technology through sales of the its core separations products and services, or as individual license agreements.
Aleš Štrancar, CEO of BIA Separations commented: “BIA Separations monolithic column technology is now well established and following this success we are focussed on providing customers with a “one-stop-shop” for the manufacture of gene therapy vectors, vaccines, exosomes, DNA/RNA and any novel complex biopharma product. To achieve fully integrated upstream and downstream processing with robust in-process control we are collaborating with other leaders in the industry to access the latest technologies and products. This agreement with the University Zagreb is one of a number currently in the pipeline and supports our ultimate goal.”
Professor Miljenko Šimpraga, Vice-rector for Innovation, Technology Transfer and Communication at the University of Zagreb added: “The University of Zagreb is pleased to see solutions developed by our researchers contributing to improvements in medical biotechnology, and being brought closer to users through our work with innovation-oriented industry partners such as BIA Separations. As a research university, this is an important achievement which is fully aligned with our aim to create a positive impact on society.”
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance